Olivia Vizier

Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication.

The FDA cleared an investigational new drug application for CYAD-211, a chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma, according to a press release from the agent’s manufacturer.

It is astounding how quickly Covid-19 vaccines have progressed into and through clinical trials. However, there are concerns that these vaccines may not be particularly effective at preventing Covid-19 infections in the long-term, leading to the need for improved, next-generation vaccines against this novel coronavirus. One pair of companies working on the next phase of

Neurodegenerative and other central nervous system disorders are some of the hardest to develop treatments for due to our limited understanding of the brain. But Cerevance developed a new technology capable of profiling neuronal and glial cell populations at depths not previously possible, which is allowing the clinical-stage pharmaceutical company to identify potential drug targets in specific

Dr. Jordan Dubow, Chief Medical Officer, Avadel Pharmaceuticals, intent on improving drug delivery technology, is focusing on narcolepsy, a disease that causes severe excessive sleepiness and in many cases cataplexy.  While there seems to be a genetic predisposition for narcolepsy, like many neurological diseases, this rare disease is difficult to diagnose with medicines that treat

At the end of April, Immunomedics (Morris Plains, N.J), a biopharmaceutical company focused on developing antibody-drug conjugates (ADC) for hard-to-treat cancers, received FDA accelerated approval for its first ADC, Trodelvy (sacituzumab govitecan-hziy). Although COVID-19 was by then in full swing, the company nonetheless pushed ahead with its launch strategy. Thanks to preparations it had begun making in

Australian company Recce Pharmaceuticals (ASX: RCE) is advancing a synthetic polymer antibiotic designed with optimum properties that exhibits high potency against a broad range of bacteria.

DURECT Corporation is advancing an epigenetic regulator program aimed at developing products to treat acute AH and nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease. DURECT’s therapeutics in development have the potential to treat multiple organ injury and chronic liver diseases.

The critical difference is that older patients and those who are immune-compromised tend to lack a robust T-cell response, which Heat Biologics believes is important in preventing the disease. With the typical flu, seniors are often prescribed a double-dose of vaccine to compensate for their inability to mount an effective adaptive response. This approach, however,

Not long ago, someone asked Lawrence Blatt, Ph.D., the probability that one of his company’s drugs would be successful. “I don’t want to think about that,” responded the CEO of Aligos Therapeutics. Blatt wasn’t trying to be coy; he knew the answer, and he knew it wouldn’t sound good.

Chiasma’s Mycapssa (octreotide) has become the first FDA-approved oral therapy to treat acromegaly, a rare disorder in which overproduction of human growth hormone leads to abnormal enlargement of patients’ extremities and internal organs, the drugmaker said.

Dr. Soon-Shiong tells PEOPLE he’s working to create a more universal cancer treatment by rethinking how we use radiation to target cancer cells – and that Reid is proof it can work. Instead of blasting the body with high doses of radiation, the doctor says the method he’s testing “tickles” the cancer cells to wake

This precise approach “makes it possible to make drugs that only act on the cell type you care about,” reducing the unwanted side effects that most drugs have, says Margus, chief executive officer of Cerevance, a Boston-based drug development company focused on brain diseases. What’s more, it could lead to a major breakthrough in the

Dr. Jonathan Javitt, the CEO of NeuroRx, said, “We’re talking to people who have critical COVID-19, with respiratory failure. That is people whose lungs have been affected by the COVID virus, such that their lungs don’t send oxygen properly to their bodies. Then the drug will be available at every hospital.”

“It’s a chronic neurodegenerative process. Chronic just means it goes on very slowly over a long period of time,” said Friedlander, of NeuBase Therapeutics. Holder’s father is at the point in his diagnosis where he often forgets a pandemic is going on. Seeing people in masks scares him.

Redhill Biopharma Ltd.’s chief operating officer, Gilead Raday, told BioWorld that the firm will build on positive results in severe COVID-19 patients with oral opaganib, a first-in-class sphingosine kinase-2 inhibitor that the company has branded Yeliva, and could seek emergency use authorization based on data due by year-end.

9 Meters Biopharma’s program for celiac disease is among the most clinically advanced programs in development. With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.

It’s early days for Cue Biopharma’s CUE-101, the lead candidate in its IL-2-based CUE-100 Series. In pre-clinical studies, CUE-101 has demonstrated selective binding and preferential activation and expansion of antigen-specific T cells, dose-dependent effector cytokine production, and inhibition of tumor growth both as a monotherapy and in combination with a PD-1 inhibitor. Its first in-human

Despite being most at risk from Covid-19, older people and those with compromised immune systems are unlikely to reap much benefit from Covid-19 vaccines, which are the main way we can overcome the viral pandemic. US-based Heat Biologics believes it has the answer to give extra protection to those with less robust immune systems.

Cidara Therapeutics (NASDAQ:CDTX) is developing what may be the first antifungal to be approved in 15 years for both the treatment and prevention of invasive fungal disease.

When Karen Jackson founded Sisters Network INC. in 1994, a national African American breast cancer survivorship organization, she was optimistic to the point of wearing rose-colored glasses about the healthcare industry. She believed that if someone was sick then there would be someone to help.Your Content Goes Here

Dr. Patrick Soon-Shiong is a physician, surgeon, researcher, philanthropist, and owner of the LA Times. From 1997–2010, he served as Founder, Chairman and CEO of American Pharmaceutical Partners (APP) and Abraxis BioScience, where he developed the drug Abraxane, which received FDA approval for the treatment of metastatic breast cancer, lung cancer, and advanced pancreatic cancer. In 2008, he

Efficacy, safety, and convenience are hard-to-achieve attributes of cancer therapies, despite the best marketing engines in biopharma. Acepodia—a clinical-stage biotech focused on developing novel, targeted, allogeneic-cell based immunotherapies to treat cancers—has the gall to add affordable to the list of product attributes it’s striving for.

Harry M. Reid has a message for these incredibly bleak times: Keep fighting. Last summer the former Senate majority leader hid from the obvious fact that pancreatic cancer was on the verge of defeating him. “I wasn’t willing to acknowledge that I was about to get hit by the Grim Reaper,” Reid (D-Nev.) said Thursday